Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide
Metadata
Show full item recordAuthor
Doello, Kevin; Chico Lozano, María Ángeles; Quiñonero Muñoz, Francisco José; Ortiz Quesada, Raúl; Prados Salazar, José Carlos; Mesas Hernández, Cristina; Melguizo Alonso, ConsolaciónEditorial
MDPI
Materia
Carcinoma Pasireotide Somatostatin receptors
Date
2024-06-25Referencia bibliográfica
Doello, K.; Chico, M.A.; Quiñonero, F.; Ortiz, R.; Prados, J.; Mesas, C.; Melguizo, C. Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide. Medicina 2024, 60, 1039. https://doi.org/10.3390/medicina60071039
Abstract
Background and Objectives: High-grade malignant neuroendocrine tumors (G3 NETs) and
neuroendocrine carcinomas (NECs) are characterized by rapid proliferation, high metastatic capacity,
and strong expression of somatostatin receptors (SSTRs). We aimed to analyze the presence of SSTRs
in NET G3 and NEC, and to correlate their expression with the use of octreotide and pasireotide.
Materials and Methods: For this purpose, we first performed a retrospective study of G3 NET and NEC
patients, which included the determination of SSTR expression and response to octreotide treatment.
Second, we selected the H69 small cell lung cancer cell line to determine the effect of octreotide and
pasireotide. Results: Our results showed the traditional somatostatin analog (SSA) octreotide was
ineffective in patients with NET G3 and NEC. On the other hand, RT-qPCR showed a high expression
of SSTR2 and SSTR5 in H69 cells. Interestingly, while octreotide did not modify H69 cell proliferation,
a strong inhibition of proliferation was detected with the use of pasireotide. Conclusions: In view of
these results, a clinical trial in NET G3 and NEC patients using pasireotide is necessary to determine
the usefulness of this drug in improving patient treatment.